Abilify (Aripiprazole) is NOT Recommended for Children with Anxiety and Depression
Aripiprazole should not be used as a treatment for pediatric anxiety or depression, as it lacks FDA approval for these indications and has no supporting evidence for efficacy, while carrying significant risks including suicidality, metabolic effects, and neurological adverse events.
Why Aripiprazole is Inappropriate
Guideline-Recommended Treatments
The 2020 AACAP guidelines for pediatric anxiety disorders are unequivocal: cognitive-behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) have considerable empirical support as safe and effective treatments 1. SNRIs represent an additional evidence-based option 1. Aripiprazole is conspicuously absent from these recommendations because it is not indicated for anxiety or depression in children.
Complete Absence of Evidence
A 2026 systematic review examining off-label antipsychotic use in children found no randomized controlled trials and no studies whatsoever on antipsychotics for pediatric anxiety disorders 2. The evidence level for depression-related disorders was rated as "very low," and the authors emphasized that "the identified very low level of evidence stands in stark contrast to clinical practice" 2.
Significant Safety Concerns
The FDA label carries a black box warning for suicidality in patients under age 24 when used for depression 3. Specifically for antidepressant indications, the pooled risk shows 1% suicidal ideation with medication versus 0.2% with placebo 1.
Aripiprazole is explicitly NOT approved for treating depression in the pediatric population 1, 3.
Documented adverse effects in children and adolescents include 4, 5:
- Chronic insomnia
- Parkinsonism and extrapyramidal symptoms
- Behavioral changes and psychoses
- Weight gain (more pronounced in children than adults)
- Neuroleptic malignant syndrome
- Suicidal behavior
- Drowsiness and sedation
A Danish case series found severe adverse events including neuroleptic malignant syndrome, extreme insomnia, and suicidal behavior in non-psychotic pediatric patients 4.
What TO Use Instead
First-Line Treatment Algorithm:
Start with CBT - Has equivalent efficacy to medication with no adverse effects 1
Add or switch to an SSRI if CBT alone is insufficient:
Consider SNRIs as an alternative if SSRIs fail 1
Critical Monitoring Points:
- Suicidality monitoring is essential in the first months and after dose changes 1, 3
- Watch for behavioral activation (restlessness, insomnia, impulsiveness, aggression) - more common in younger children and anxiety disorders 1
- Screen for bipolar disorder before starting antidepressants, as treating unrecognized bipolar with antidepressants alone may precipitate mania 3
The Bottom Line
While aripiprazole has proven efficacy for schizophrenia, bipolar disorder, autism-related irritability, and Tourette's in children 5, 6, 7, it has no role in treating pediatric anxiety or depression. The combination of zero supporting evidence, lack of FDA approval, and significant adverse effect risks makes this an inappropriate choice. Stick with evidence-based treatments: CBT and SSRIs 1.